Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zaltenibart by Omeros for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase...
Zaltenibart by Omeros for Kidney Disease (Nephropathy): Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase...
Zaltenibart by Omeros for Glomerulonephritis: Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase II for Glomerulonephritis. According to GlobalData, Phase II drugs...